Transgenic expression of full-length 2′,5′-oligoadenylate synthetase 1b confers to BALB/c mice resistance against West Nile virus-induced encephalitis

Mouse Functional Genetics, Institut Pasteur, Paris, France.
Virology (Impact Factor: 3.32). 06/2011; 417(1):147-53. DOI: 10.1016/j.virol.2011.05.018
Source: PubMed


Susceptibility of inbred strains to infection with West Nile virus (WNV) has been genetically associated with an arginine-to-a nonsense codon substitution at position 253 (R253X) in the predicted sequence of the murine 2',5'-oligoadenylate synthetase 1B (OAS1B) protein. We introduced by transgenesis the Oas1b cDNA from MBT/Pas mice carrying the R253 codon (Oas1b(MBT)) into BALB/c mice homozygous for the X253 allele (Oas1b(BALB/c)). Overexpression of Oas1b(MBT) mRNA in the brain of transgenic mice prior and in the time course of infection provided protection against the neuroinvasive WNV strain IS-98-ST1. A 200-fold induction of Oas1b(MBT) mRNA in the brain of congenic BALB/c mice homozygous for a MBT/Pas segment encompassing the Oas1b gene was also efficient in reducing both viral growth and mortality, whereas a 200-fold induction of Oas1b(BALB/c) mRNA was unable to prevent virally-induced encephalitis, confirming the critical role of the R253X mutation on Oas1b activity in live mice.

Download full-text


Available from: Jean-Jacques Panthier, Mar 18, 2014
  • Source
    • "During the 1998 epidemic in Israel, WNV strain IS-98-ST1 was isolated from a stork with severe neurological symptoms [20]. IS-98-ST1 is suitable for the study of viral determinants of WNV virulence, as well as host factors involved in viral pathogenicity [21], [22], [23], [24], [25]. To date, a few molecular clones derived from North American, African and Australian strains of WNV are available for the study of viral neuropathogenicity [1], [3], [9], [26], [27], [28]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Infectious clones of West Nile virus (WNV) have previously been generated and used to decipher the role of viral proteins in WNV virulence. The majority of molecular clones obtained to date have been derived from North American, Australian, or African isolates. Here, we describe the construction of an infectious cDNA clone of a Mediterranean WNV strain, IS-98-ST1. We characterized the biological properties of the recovered recombinant virus in cell culture and in mice. The growth kinetics of recombinant and parental WNV were similar in Vero cells. Moreover, the phenotype of recombinant and parental WNV was indistinguishable as regards viremia, viral load in the brain, and mortality in susceptible and resistant mice. Finally, the pathobiology of the infectious clone was examined in embryonated chicken eggs. The capacity of different WNV strains to replicate in embryonated chicken eggs closely paralleled their ability to replicate in mice, suggesting that inoculation of embryonated chicken eggs could provide a practical in vivo model for the study of WNV pathogenesis. In conclusion, the IS-98-ST1 infectious clone will allow assessment of the impact of selected mutations and novel genomic changes appearing in emerging European strains pathogenicity and endemic or epidemic potential. This will be invaluable in the context of an increasing number of outbreaks and enhanced severity of infections in the Mediterranean basin and Eastern Europe.
    PLoS ONE 10/2012; 7(10):e47666. DOI:10.1371/journal.pone.0047666 · 3.23 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Type I interferon (IFN) signaling coordinates an early antiviral program in infected and uninfected cells by inducing IFN-stimulated genes (ISGs) that modulate viral entry, replication, and assembly. However, the specific antiviral functions in vivo of most ISGs remain unknown. Here, we examined the contribution of the ISG viperin to the control of West Nile virus (WNV) in genetically deficient cells and mice. While modest increases in levels of WNV replication were observed for primary viperin(-/-) macrophages and dendritic cells, no appreciable differences were detected in deficient embryonic cortical neurons or fibroblasts. In comparison, viperin(-/-) adult mice infected with WNV via the subcutaneous or intracranial route showed increased lethality and/or enhanced viral replication in central nervous system (CNS) tissues. In the CNS, viperin expression was induced in both WNV-infected and adjacent uninfected cells, including activated leukocytes at the site of infection. Our experiments suggest that viperin restricts the infection of WNV in a tissue- and cell-type-specific manner and may be an important ISG for controlling viral infections that cause CNS disease.
    Journal of Virology 08/2011; 85(22):11557-66. DOI:10.1128/JVI.05519-11 · 4.44 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Developing treatments aimed at the causes of diseases such as cancer, infections and metabolic, autoimmune and psychiatric disorders requires knowledge of the underlying biological mechanisms. Such knowledge can only be obtained by functional studies in which the disease-relevant tissue and the course of disease are manipulated systematically, e.g., pharmacologically, environmentally or genetically. Experimental models are fundamental for meeting these challenges, and biomedical scientists often select mice as models. However, it is often difficult for the outsider to appreciate the translational value of mouse models. That ‘mice are not humans’ is obvious, but the use of experimental models in biomedical research has a dual function: discovery of basic biological mechanisms and development of new drugs and treatments. In this article, the members of the SYSGENET network recount some seminal studies on mouse models that provided key insights into the biology of human diseases and paved the way for the development of novel therapeutic approaches. SYSGENET represents a network of European scientists who use mouse genetic reference populations (GRPs) to understand complex genetic factors influencing disease phenotypes
    European Journal of HumanGenetics 05/2013; May 1(11). DOI:10.1038/ejhg.2013.79 · 4.35 Impact Factor
Show more